.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Covington
Federal Trade Commission
Moodys
Cerilliant
Citi
Novartis
Merck
Deloitte
Healthtrust

Generated: November 21, 2017

DrugPatentWatch Database Preview

KENGREAL Drug Profile

« Back to Dashboard

Which patents cover Kengreal, and when can generic versions of Kengreal launch?

Kengreal is a drug marketed by Chiesi Usa Inc and is included in one NDA. There are eight patents protecting this drug.

This drug has one hundred and twenty-six patent family members in thirty-nine countries and one supplementary protection certificate in one country.

The generic ingredient in KENGREAL is cangrelor. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the cangrelor profile page.
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chiesi Usa Inc
KENGREAL
cangrelor
POWDER;IV (INFUSION)204958-001Jun 22, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Chiesi Usa Inc
KENGREAL
cangrelor
POWDER;IV (INFUSION)204958-001Jun 22, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Chiesi Usa Inc
KENGREAL
cangrelor
POWDER;IV (INFUSION)204958-001Jun 22, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Chiesi Usa Inc
KENGREAL
cangrelor
POWDER;IV (INFUSION)204958-001Jun 22, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Chiesi Usa Inc
KENGREAL
cangrelor
POWDER;IV (INFUSION)204958-001Jun 22, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Chiesi Usa Inc
KENGREAL
cangrelor
POWDER;IV (INFUSION)204958-001Jun 22, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Chiesi Usa Inc
KENGREAL
cangrelor
POWDER;IV (INFUSION)204958-001Jun 22, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Chiesi Usa Inc
KENGREAL
cangrelor
POWDER;IV (INFUSION)204958-001Jun 22, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Chiesi Usa Inc
KENGREAL
cangrelor
POWDER;IV (INFUSION)204958-001Jun 22, 2015RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: KENGREAL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,716,261Maintenance of platelet inhibition during antiplatelet therapy► Subscribe
9,320,754Maintenance of platelet inhibition during antiplatelet therapy► Subscribe
8,871,736Maintenance of platelet inhibition during antiplatelet therapy► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: KENGREAL

Country Document Number Estimated Expiration
Spain2182133► Subscribe
China106102750► Subscribe
Saudi Arabia1126► Subscribe
Australia2010319612► Subscribe
Taiwan522015► Subscribe
Japan4488538► Subscribe
European Patent Office1000079► Subscribe
Hong Kong1026429► Subscribe
Czech Republic298110► Subscribe
China102089035► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: KENGREAL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0060France► SubscribePRODUCT NAME: CANGRELOR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,NOTAMMENT UN SEL TETRASODIQUE; REGISTRATION NO/DATE: EU/1/15/994/001 20150323
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Express Scripts
Cerilliant
US Army
McKesson
Moodys
Argus Health
Queensland Health
Fish and Richardson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot